Free Trial

Gemini Therapeutics (GMTX) Competitors

Gemini Therapeutics logo
$56.91 -1.09 (-1.88%)
As of 07/11/2025

GMTX vs. BBIO, BPMC, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and NUVL

Should you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

Gemini Therapeutics vs. Its Competitors

Gemini Therapeutics (NASDAQ:GMTX) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

BridgeBio Pharma has a consensus price target of $60.21, indicating a potential upside of 29.58%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Gemini Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gemini Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
BridgeBio Pharma
0 Sell rating(s)
0 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
3.00

Gemini Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Gemini Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gemini TherapeuticsN/AN/A-$71.87M-$1.00-56.91
BridgeBio Pharma$127.42M69.25-$535.76M-$3.53-13.16

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Gemini Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Gemini Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gemini TherapeuticsN/A -38.78% -35.88%
BridgeBio Pharma -524.25%N/A -94.43%

Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

In the previous week, BridgeBio Pharma had 12 more articles in the media than Gemini Therapeutics. MarketBeat recorded 12 mentions for BridgeBio Pharma and 0 mentions for Gemini Therapeutics. BridgeBio Pharma's average media sentiment score of 0.85 beat Gemini Therapeutics' score of 0.00 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Gemini Therapeutics Neutral
BridgeBio Pharma Positive

Summary

BridgeBio Pharma beats Gemini Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Gemini Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GMTX vs. The Competition

MetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2.47B$839.37M$5.55B$9.09B
Dividend YieldN/A4.84%5.25%4.02%
P/E Ratio-56.911.3828.2620.27
Price / SalesN/A241.37408.79151.98
Price / CashN/A17.6937.1257.67
Price / Book19.696.588.045.49
Net Income-$71.87M-$23.83M$3.19B$250.45M
7 Day Performance3.95%1.59%3.62%4.79%
1 Month Performance7.97%-0.08%5.98%9.59%
1 Year Performance20.65%4.35%29.39%16.41%

Gemini Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GMTX
Gemini Therapeutics
N/A$56.91
-1.9%
N/A+21.3%$2.47BN/A-56.9130
BBIO
BridgeBio Pharma
4.663 of 5 stars
$43.50
-1.1%
$58.85
+35.3%
+71.3%$8.35B$221.90M-12.32400Analyst Upgrade
BPMC
Blueprint Medicines
1.2207 of 5 stars
$128.40
+0.0%
$128.25
-0.1%
+9.8%$8.29B$508.82M-51.98640Positive News
Insider Trade
VRNA
Verona Pharma PLC American Depositary Share
2.3773 of 5 stars
$91.20
-0.4%
$107.36
+17.7%
+403.5%$7.79B$42.28M-45.6030Trending News
Analyst Forecast
ROIV
Roivant Sciences
2.9967 of 5 stars
$10.74
-2.3%
$17.50
+62.9%
+0.1%$7.47B$29.05M-42.96860News Coverage
Positive News
Analyst Upgrade
ELAN
Elanco Animal Health
1.4946 of 5 stars
$14.48
-1.1%
$15.33
+5.9%
+7.9%$7.27B$4.44B19.579,000News Coverage
RVMD
Revolution Medicines
4.489 of 5 stars
$36.67
-3.2%
$68.00
+85.4%
-15.8%$7.05B$11.58M-9.17250
LEGN
Legend Biotech
3.3796 of 5 stars
$35.87
+0.6%
$72.60
+102.4%
-28.3%$6.55B$627.24M-60.802,609Analyst Forecast
GRFS
Grifols
3.565 of 5 stars
$8.87
-2.3%
$10.30
+16.1%
+17.9%$6.24B$7.81B7.5823,822News Coverage
TGTX
TG Therapeutics
3.6913 of 5 stars
$35.98
-2.0%
$40.80
+13.4%
+75.0%$5.83B$329M149.92290News Coverage
Positive News
Analyst Upgrade
NUVL
Nuvalent
3.3636 of 5 stars
$77.93
-3.2%
$119.60
+53.5%
+2.9%$5.78BN/A-17.7540Insider Trade

Related Companies and Tools


This page (NASDAQ:GMTX) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners